Immix Biopharma (IMMX) Depreciation and Depletion (2021 - 2026)

Immix Biopharma has disclosed Depreciation and Depletion across 6 years of filings, most recently posting $91577.0 for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $91577.0, up 140.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $299171.0 (up 339.41% YoY), and the FY2025 annual result was $245747.0, up 646.02% from the prior year.
• Depreciation and Depletion came in at $91577.0 for Q1 2026 at Immix Biopharma, up from $52114.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $96986.0 in Q3 2025 to a low of $383.0 in Q2 2022.
• The 5-year median for Depreciation and Depletion is $3076.0 (2023), against an average of $22227.5.
• Across the five-year window, Depreciation and Depletion slumped 38.23% in 2022 and surged 1679.89% in 2025, its largest moves.
• Immix Biopharma's Depreciation and Depletion stood at $566.0 in 2022, then soared by 443.46% to $3076.0 in 2023, then jumped by 569.8% to $20603.0 in 2024, then soared by 152.94% to $52114.0 in 2025, then soared by 75.72% to $91577.0 in 2026.
• The last three Depreciation and Depletion figures came in at $91577.0 (Q1 2026), $52114.0 (Q4 2025), and $96986.0 (Q3 2025), per Business Quant data.